As per MRFR analysis, the Opioid Use Disorder Market Size was estimated at 6.44 (USD Billion) in 2023. The Opioid Use Disorder Market Industry is expected to grow from 6.67(USD Billion) in 2024 to 9.8 (USD Billion) by 2035.
The Opioid Use Disorder Market CAGR (growth rate) is expected to be around 3.56% during the forecast period (2025 - 2035).
The Global Opioid Use Disorder Market is experiencing several significant trends driven by an increased emphasis on comprehensive treatment approaches. The rising prevalence of opioid use disorder worldwide has prompted governments and healthcare organizations to allocate more resources to prevention and treatment programs.
Key market drivers include the growing awareness of the importance of addiction as a public health issue, which has led to improved access to innovative therapies and harm-reduction strategies. There is also a noticeable shift towards using medication-assisted treatment (MAT) as a standard part of the care protocol, which combines behavioral therapies with medications, offering patients a multifaceted approach to recovery.
The development of novel pharmacological solutions and digital health technologies that can improve treatment engagement and adherence presents opportunities for growth. The integration of telemedicine has arisen as a substantial opportunity, enabling improved access to treatment, particularly in remote or underserved regions. There has been a recent trend toward the integration of social support systems into treatment programs, as it is acknowledged that community involvement is essential for the long-term maintenance of recovery.
Additionally, the design and implementation of interventions are being transformed by the growing emphasis on personalized medicine. Better results can be achieved by tailoring treatment plans to the unique requirements and backgrounds of each patient. The significance of regulatory frameworks in regulating the prescribing of opioids and related substances is also increasing as a result of the efforts of various jurisdictions to balance the risk of potential misuse with pain management.
In general, the market is adapting to address the intricacies of opioid use disorder through a more comprehensive and patient-centered approach.
  
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Global Opioid Use Disorder Market Industry is significantly driven by the increasing prevalence of opioid use disorders across various demographics. According to the National Institute on Drug Abuse, around 2 million Americans were suffering from opioid use disorders in 2018, a number that has only increased over the years. Furthermore, the World Health Organization estimates that approximately 27 million individuals worldwide have problematic use of opioids, which is indicative of a growing global epidemic.
This rise is largely attributed to prescription practices that encourage misusage and addiction, prompting global health organizations, such as the World Health Organization and the Centers for Disease Control and Prevention, to collaborate in initiatives aimed at overcoming this crisis.
This reaction highlights the urgency and necessity for innovative treatment options within the Global Opioid Use Disorder Market Industry, spurred by the imperative need for new therapeutics and rehabilitation solutions.
Government interventions play a critical role in the growth of the Global Opioid Use Disorder Market Industry. Various countries are implementing comprehensive strategies to combat the opioid crisis, including increased funding for treatment programs and educational campaigns aimed at prescribers and communities. For example, in 2021, the U.S. Department of Health and Human Services announced the allocation of over USD 1.5 billion in grants to support state-level initiatives to reduce opioid overdoses and expand access to treatment.
This direct financial support fosters innovation in treatment, encouraging pharmaceutical companies and healthcare providers to develop and implement new therapies aimed at addressing opioid use disorders.
The Global Opioid Use Disorder Market Industry is also propelled by significant advancements in treatment methodologies, including the development of new medications and therapies. For instance, the approval of buprenorphine and naloxone combination therapy has revolutionized treatment approaches, leading to improved patient outcomes.
The National Institutes of Health reports that medication-assisted treatment can significantly reduce the risk of overdose and encourage retention in treatment programs, which are vital metrics for combating opioid disorders.
Such advancements not only provide healthcare professionals with effective treatment options but also reflect the growing commitment of pharmaceutical companies to invest in Research and Development, thus uplifting the Global Opioid Use Disorder Market Industry.
The Global Opioid Use Disorder Market has been categorized by Treatment Type, which encompasses crucial areas such as Medications, Therapies, and Counseling. In 2024, the overall market valuation reached 6.67 USD Billion, indicating a strong focus on various treatment-like modalities for opioid addiction.
Medications currently dominate the landscape, accounting for a significant 4.0 USD Billion of the total valuation in 2024, and projected to grow to 5.5 USD Billion by 2035. This segment is essential due to the role of pharmacological interventions in managing withdrawal symptoms, reducing cravings, and preventing relapse in individuals suffering from opioid use disorder.
The effectiveness of medications like buprenorphine and methadone further solidifies this category's importance by providing life-saving treatments that help patients stabilize their lives.
Therapies, valued at 1.8 USD Billion in 2024, are also projected to increase to 2.5 USD Billion by 2035. This segment includes various behavioral and alternative therapeutic models designed to address the psychological aspects of addiction. The significance of therapy lies in its ability to complement medication-assisted treatments and empower individuals to cope with triggers, develop coping strategies, and reconstruct their social relationships.
As these treatment modalities are integrated into comprehensive care plans, they enhance overall recovery outcomes for individuals faced with opioid dependence. Counseling, while comparatively smaller, represents a crucial component of the treatment equation, with a market value of 0.87 USD Billion in 2024 poised to double to 1.8 USD Billion by 2035.
This segment focuses on the critical communication aspects between professionals and patients, allowing for individualized support and coping mechanisms tailored to each individual's unique experiences and backgrounds.
Counseling plays a supportive role, filling gaps that are often left unaddressed by medication alone and emphasizing the importance of emotional and psychological well-being in the recovery process.
Considering the collective insights from the Global Opioid Use Disorder Market data, Medications, Therapies, and Counseling not only demonstrate a growing market presence but underscore the multifaceted approach required to tackle opioid addiction effectively. This growth can be attributed to an increasing awareness of opioid use disorder and the ongoing commitment from various stakeholders toward developing more integrated and effective treatment solutions.
The demand for diverse treatment strategies highlights emerging opportunities, and both healthcare providers and policymakers are examining new pathways to make treatment more accessible and effective, thereby addressing one of the most pressing health crises on a global scale.
As the landscape continues to evolve, the segmented approach offers a comprehensive understanding of how each treatment method contributes uniquely to recovery and highlights the importance of a coordinated healthcare response to this enduring challenge.
  
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Global Opioid Use Disorder Market, valued at 6.67 billion USD in 2024, places significant emphasis on the Administration Route segment. This segment is crucial in defining how treatments for opioid use disorder are delivered to patients, impacting their effectiveness and patient adherence.
The major routes include Oral, Injectable, and Transdermal administration methods, each presenting unique advantages. Oral medications are often preferred for their ease of use and accessibility, leading to higher patient compliance. Injectable routes provide rapid effects and are suitable for patients requiring immediate intervention.
Meanwhile, Transdermal applications offer a steady release of medication, enhancing convenience for long-term treatment. The diversification within the Administration Route is driven by the growing need for effective and user-friendly treatment options, fostering market growth.
According to various industry sources, trends indicate that the demand for personalized and efficient treatment approaches will continue to rise, with these administration methods playing a pivotal role in addressing the complexities of opioid use disorder effectively. As the market evolves, ongoing research and legislative support globally are anticipated to enhance the accessibility and development of these critical administration methodologies.
The Global Opioid Use Disorder Market is intricately segmented by Patient Age Group, which includes Adolescents, Adults, and Geriatrics, reflecting diverse challenges and requirements within the treatment landscape. In 2024, the Global Opioid Use Disorder Market revenue is expected to reach approximately 6.67 billion USD, reflecting the increasing recognition of opioid dependency across age demographics.
Adults represent a significant portion of the market, as they face higher rates of opioid misuse; this group's treatment options are expanding, emphasizing the importance of personalized care strategies.
Furthermore, Adolescents are emerging as a critical segment, necessitating targeted interventions due to the rising prevalence of substance abuse in this age group, which underscores the need for education and early prevention. The Geriatrics segment is also crucial, given that older adults often grapple with chronic pain management, leading to a complex relationship with opioid prescriptions.
Overall, the Global Opioid Use Disorder Market industry is witnessing growth driven primarily by increasing awareness, improved access to treatment, and the integration of mental health support, yet it faces challenges such as stigma and varying regulations across regions.
This market segmentation reveals unique insights crucial for tailoring effective treatment strategies and addressing the needs of each group within the global context.
The Global Opioid Use Disorder Market is projected to reach a valuation of 6.67 billion USD in 2024, growing to 9.8 billion USD by 2035. This market is characterized by its diverse settings, which include inpatient, outpatient, and residential treatment options.
Inpatient settings offer comprehensive care and are essential for individuals requiring intensive support, often leading to higher recovery rates due to close monitoring. Outpatient care facilitates flexibility, allowing patients to engage in their daily lives while receiving necessary treatment, which is crucial for maintaining a connection to their community as they recover.
Residential treatment provides a stable environment, fostering a sense of community and support among patients. The Global Opioid Use Disorder Market segmentation highlights that different settings cater to various patient needs, reflecting a significant opportunity for growth driven by increasing awareness and destigmatization of treatment options.
Challenges such as regulatory hurdles and access to care remain, but expanding treatment accessibility will be vital for future market growth. Understanding these settings is key to addressing the opioid crisis globally, as they directly impact recovery outcomes and patient engagement in their treatment journey.
The Global Opioid Use Disorder Market exhibits significant growth potential across various regions, with a projected valuation of 6.67 USD Billion in 2024, increasing to 9.8 USD Billion by 2035.
North America leads the market with a valuation of 3.5 USD Billion in 2024 and a growth to 5.0 USD Billion in 2035, largely due to its high prevalence of opioid addiction and strong healthcare infrastructure. Europe follows with a valuation of 1.5 USD Billion in 2024, growing to 2.1 USD Billion in 2035, reflecting increasing awareness and treatment initiatives.
The Asia-Pacific (APAC) region is also showing promise, valued at 1.3 USD Billion in 2024 and expected to rise to 1.8 USD Billion by 2035, driven by a growing population and increasing substance abuse prevalence. South America, while smaller, holds a valuation of 0.2 USD Billion in 2024 and is expected to reach 0.3 USD Billion in 2035, highlighting emerging opportunities for market growth.
The Middle East and Africa (MEA) segment, currently valued at 0.17 USD Billion in 2024, is projected to grow to 0.2 USD Billion in 2035. This regional overview reflects key drivers, such as heightened awareness, supportive government policies, and a growing emphasis on treatment services in the Global Opioid Use Disorder Market.
  
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Global Opioid Use Disorder Market is characterized by a complex landscape shaped by increasing awareness regarding the opioid crisis, the need for effective treatment solutions, and the involvement of various stakeholders, including pharmaceutical companies, healthcare providers, and regulatory bodies.
The market comprises a range of therapeutic options aimed at managing opioid dependence, which has seen rising prevalence across the globe. Competitive insights in this sector reveal that the market is driven by innovation in drug formulations, regulatory approvals, and the establishment of partnerships that bolster market penetration. Companies are continually developing new strategies to strengthen their positions and address the changing landscape presented by increased regulations and market demands.
Pfizer has a significant presence in the Global Opioid Use Disorder Market through its commitment to developing innovative therapies and maintaining a strong market presence. The company is recognized for its extensive research and development capabilities, which facilitate the introduction of advanced treatment options aimed at addressing the needs of patients suffering from opioid use disorder.
Pfizer's strong brand equity and operational scale allow it to leverage avenues for growth within the market, including collaborations with healthcare organizations and advocacy for increased education about opioid dependency and treatment solutions. Its ability to launch effective marketing campaigns and engage with various stakeholders enhances its visibility and strengthens its competitive edge in the field.
Sandoz, as a subsidiary of Novartis, plays a crucial role in the Global Opioid Use Disorder Market by focusing on providing high-quality generics and biosimilars. The company emphasizes affordable treatment options that cater to a wide range of patients, enhancing access to essential medications. Sandoz offers important products that aid in the management of opioid use disorder, aligning with market needs while also prioritizing safety and patient outcomes.
The strength of Sandoz lies not only in its diverse product portfolio but also in its strategic mergers and acquisitions that have allowed it to strengthen its market position globally. Through these initiatives, Sandoz continues to solidify its commitment to addressing the opioid crisis while remaining competitive through effective utilization of resources and innovation in dosage forms and delivery mechanisms.
Recent developments in the Global Opioid Use Disorder Market include ongoing efforts to address the addiction crisis, with pharmaceutical companies such as Indivior and Otsuka Pharmaceutical working on innovative treatments to enhance patient compliance and outcomes.
In August 2023, Boehringer Ingelheim announced a partnership with Galena Biopharma aimed at expanding treatment options for opioid use disorder, a move expected to bolster their portfolio in this critical area. The market valuation experienced noticeable growth, driven in part by increased awareness and funding for opioid addiction treatment programs globally.
This has led companies like Pfizer and Amgen to invest heavily in Research and Development for new therapeutic options. Notably, in September 2022, Mallinckrodt successfully completed its restructuring with a focus on opioid-related therapies, highlighting the shifting landscape in the industry.
Additionally, strategic acquisitions and collaborations are increasingly common, with companies looking to enhance their capabilities in addressing opioid use issues. Recent dialogues among industry players emphasize the importance of regulatory compliance and the need for community-focused initiatives to combat the opioid crisis effectively.
This ongoing evolution reflects a collective commitment to innovative solutions within the Global Opioid Use Disorder Market.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 6.44(USD Billion) |
| MARKET SIZE 2024 | 6.67(USD Billion) |
| MARKET SIZE 2035 | 9.8(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.56% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Pfizer, Sandoz, Amgen, AbbVie, Novo Nordisk, Otsuka Pharmaceutical, Boehringer Ingelheim, Galena Biopharma, Teva Pharmaceutical Industries, BristolMyers Squibb, Mylan, Hikma Pharmaceuticals, Indivior, Mallinckrodt, Eli Lilly and Company |
| SEGMENTS COVERED | Treatment Type, Administration Route, Patient Age Group, Setting, Regional |
| KEY MARKET OPPORTUNITIES | Telehealth for addiction treatment, Increased demand for long-acting medications, Expansion of harm reduction programs, Innovative personalized therapies, Enhanced patient education and support services |
| KEY MARKET DYNAMICS | rising addiction rates, increasing treatment options, regulatory changes, growing awareness campaigns, emerging telehealth solutions |
| COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Global Opioid Use Disorder Market is expected to be valued at 6.67 USD Billion in 2024.
The market is expected to grow at a CAGR of 3.56% between 2025 and 2035.
The North American segment is projected to be valued at 3.5 USD Billion in 2024.
The medications segment is expected to reach 5.5 USD Billion by 2035.
The counseling services segment is valued at 0.87 USD Billion in 2024.
The Europe region is projected to have a market value of 2.1 USD Billion in 2035.
The therapy segment is expected to grow to 2.5 USD Billion by 2035.
Major players include Pfizer, Sandoz, Amgen, AbbVie, and Otsuka Pharmaceutical.
The South American segment is projected to reach 0.3 USD Billion in 2035.
The MEA region is expected to contribute approximately 0.17 USD Billion in 2024.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
